Pacira: Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

 — EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies — 

— New indications for use as an adductor canal block and sciatic nerve block in the popliteal fossa will significantly extend reach within more than 3 million lower extremity procedures —

https://www.globenewswire.com/news-release/2023/11/10/2778236/0/en/Pacira-Announces-FDA-Approval-of-Expanded-EXPAREL-Label-to-Include-Two-Additional-Nerve-Block-Indications.html